Abstracts Archive - Page 2035 of 2607 - ACR Meeting Abstracts

Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting
Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis
Ayumi Nishikawa¹, Katsuya Suzuki², Yoshiaki Kassai³, Yuumi Gotou⁴, Takahiro Miyazaki³, Maiko Takiguchi⁵, Masaru Takeshita¹, Atsuko Murota², Rimpei Morita⁶, Akihiko Yoshimura⁶ and Tsutomu Takeuchi², ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁵Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, ⁶Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…
Abstract Number: 2978 • 2014 ACR/ARHP Annual Meeting
Characterization of the Sjögren’s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1)
John A. Ice¹, He Li^2,3, Indra Adrianto², Mikhail G. Dozmorov⁴, Astrid Rasmussen⁵, Graham B. Wiley¹, Jennifer A. Kelly¹, Kimberly S. Hefner⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, David M. Lewis⁹, Stephen Young⁹, Michael D. Rohrer⁸, Juan-Manuel Anaya¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², Nelson L. Rhodus¹³, Lida Radfar¹⁴, Michael H. Weisman¹⁵, Judith A. James^16,17, Courtney G. Montgomery¹⁸, R. Hal Scofield^19,20,21, Patrick M. Gaffney¹, Linda F. Thompson²², A. Darise Farris²³, Susan Kovats¹, Jonathan D. Wren¹, Kathy L. Sivils²⁴ and Christopher J. Lessard²⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³University of Minnesota, Minneapolis, MN, ¹⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²⁰College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ²⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁵825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Sjögren’s syndrome (SS) is a common autoimmune disorder characterized by immune-mediated exocrine gland destruction and systemic inflammatory responses that contribute to clinical heterogeneity. Widespread…
Abstract Number: 2979 • 2014 ACR/ARHP Annual Meeting
Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Wouter Beumer¹, Zana Brkic¹, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Peter J. van der Spek², Hemmo A. Drexhage¹ and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by autoantibodies targeting RNA-associated antigens, anti-SSA/SSB. The IFN-signature is present in over half of…
Abstract Number: 2980 • 2014 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren’s Syndrome
Gunnel Nordmark¹, Juliana Imgenberg-Kreuz², Jonas Carlsson Almlöf², Jessica Nordlund², Roald Omdal³, Katrine B. Norheim³, Maija-Leena Eloranta⁴, Lars Rönnblom⁴ and Johanna K. Sandling², ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose Increasing evidence suggests an epigenetic contribution to the pathogenesis of autoimmune diseases, including primary Sjögren’s Syndrome (pSS) (1). A genome-wide DNA methylation study in…
Abstract Number: 2981 • 2014 ACR/ARHP Annual Meeting
Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren’s Syndrome at Lymphoma Risk
Chiara Baldini¹, Eleonora Santini², Chiara Rossi², Francesca Sernissi¹, Daniela Martini¹, Alessia Gallo³, Valentina Donati², Nicoletta Luciano¹, Francesco Ferro¹, Illias Alevizos⁴, Anna Solini² and Stefano Bombardieri⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Sjogren's Clinic, NIDCR, Bethesda, MD, ⁴NIDCR, Bethesda, MD, ⁵Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Pro-inflammatory P2X7-receptor has been recently implicated in the pathogenesis of primary Sjögren’s syndrome (pSS), suggesting that it may be involved in the initiation and…
Abstract Number: 2982 • 2014 ACR/ARHP Annual Meeting
Identification of Whole Blood Gene Expression Signature in Primary Sjögren’s Syndrome Associated Lymphoma
Shereen Al-Ali^1,2, Simon Cockell³, Andrew Skelton⁴, Katherine James¹, Jessica Tarn¹, David Young⁵, Bridget Griffiths⁶, Simon Bowman⁷, James Locke¹ and Wan-Fai Ng⁸, ¹Newcastle University, Newcastle upon Tyne, United Kingdom, ²College of Science, University of Basrah, Basrah, Iraq, ³Bioinformatics Support Unit, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Bioinformatics support unit, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁶Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ⁷Rheumatology Dept (Selly Oak), University Hospital Birmingham, Birmingham, United Kingdom, ⁸Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjӧgren’s syndrome (pSS) is associated with a substantially increased risk of lymphoma development. The aim of our study is to identify a whole…
Abstract Number: 2983 • 2014 ACR/ARHP Annual Meeting
Infliximab Added to Naproxen Does Not Increase Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints and of the Spine As Compared to Naproxen Alone in Early Axial Spondyloarthritis
Denis Poddubnyy and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Fatty lesions of the bone marrow in the axial skeleton (sacroiliac joints – SIJ, and spine) on magnetic resonance imaging (MRI) are considered nowadays…
Abstract Number: 2984 • 2014 ACR/ARHP Annual Meeting
Degenerative Changes of the Spine on MRI in Patients with Inflammatory Back Pain from the DESIR Cohort
F. de Bruin¹, Marc Olivier Treyvaud², Antoine Feydy², Maxime Dougados³, Laure Gossec⁴, J.L Bloem¹, Désirée van der Heijde⁵ and Monique Reijnierse⁵, ¹Radiology, Leiden University Medical Center, Leiden, Netherlands, ²Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France, ³Descartes University, Cochin Hospital, Paris, France, ⁴Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose MRI is a sensitive method to detect early signs of axial spondyloarthritis (axSpA). A positive MRI of the sacroiliac joints is part of the…
Abstract Number: 2985 • 2014 ACR/ARHP Annual Meeting
Autoantibodies to 14-3-3η Are Novel Biomarkers Associated with Inflammation and Radiographic Progression in Ankylosing Spondylitis
Walter P. Maksymowych¹, Stephanie Wichuk¹, RG Lambert², Mairead Murphy³ and Anthony Marotta⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Radiology, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a ubiquitous intracellular chaperone protein that is expressed extracellularly in rheumatoid arthritis and mediates inflammatory cascades that result in expression of inflammatory…
Abstract Number: 2986 • 2014 ACR/ARHP Annual Meeting
Fat Metaplasia on MRI of the Sacroiliac Joints Is a Lead Indicator of Radiographic Progression in the Spine of Patients with Ankylosing Spondylitis
Walter P. Maksymowych¹, S Wichuk², P Chiowchanwisawakit³, RG Lambert⁴ and Sj Pedersen⁵, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Mahidol University, Bangkok, Thailand, ⁴Radiology, University of Alberta, Edmonton, AB, Canada, ⁵Dept. of Rheumatology, Copenhagen Center for Arthritis Research, Copenhagen, Denmark
Fat Metaplasia on MRI of the Sacroiliac joints is a Lead Indicator of Radiographic Progression in the Spine of Patients with Ankylosing SpondylitisMaksymowych WP, Wichuk…
Abstract Number: 2987 • 2014 ACR/ARHP Annual Meeting
Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Chronic Low Back Pain
Maximiliano Bravo¹, Leandro Ferreyra Garrott¹, David A. Navarta², Emmanuel Bertiller¹, Ricardo Garcia-Monaco³, Santiago Ruta¹, Javier Rosa⁴ and Enrique Soriano¹, ¹Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The utility of ultrasound in the evaluation of sacroiliitishas not been extensively studied yet. To evaluate the diagnostic value of color Doppler ultrasound (US) for…
Abstract Number: 2988 • 2014 ACR/ARHP Annual Meeting
Calgranulin Levels Are Elevated in Spondyloarthritis and Reflect the Presence of Acute Microscopic Gut Inflammation
Heleen Cypers¹, Gaëlle Varkas¹, Liesbet Van Praet¹, Johannes Roth², Thomas Vogl², Claude Cuvelier³, Dirk Föll⁴, Miha Lavric⁵, Filip van Den Bosch¹ and Dirk Elewaut¹, ¹Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ³Pathology, Department of Pathology Ghent University Hospital, Ghent, Belgium, ⁴Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ⁵University Children's Hospital Muenster, Muenster, Germany
Background/Purpose: Microscopic gut inflammation is present in about 50% of spondyloarthritis (SpA) patients. Two types can be distinguished: an acute type resembling infectious enterocolitis, and…
Abstract Number: 2989 • 2014 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcomes (PRO) are important to understand, educate, manage and follow patients with systemic lupus erythematosus (SLE). Lupus Impact Tracker (LIT) is a…
Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study
Javier Merayo-Chalico¹, Elia Apodaca², Ana Barrera-Vargas³, Jorge Alcocer-Varela³ and Diana Gómez-Martín³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
Abstract Number: 2991 • 2014 ACR/ARHP Annual Meeting
Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Complications of neuropsychiatric systemic lupus erythematosus (NP-SLE) are associated with the morbidity and mortality of patients with SLE. Although the detailed pathophysiology of NP-SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].